Inhibiting SREBP and subsequently suppressing NF-κB-related inflammatory responses may alleviate inflammation, inhibit bone destruction, reduce disability, and achieve disease remission in RA patients (Figure 3). Here, NFKB1 is linked to rheumatoid arthritis.